Loading tape…Loading tape…
NTRA
NTRA
NTRA
As media discussions highlight 'The Top HealthTech Questions Landing on Our Desks', Natera Inc's fundamental profile reflects notable scale alongside ongoing profitability challenges. The company operates with a market cap of 47,000,298,700 and generated full-year revenue of 2,306,113,000. Meanwhile, its trailing twelve-month EPS stands at -1.3424577223459124, paired with a PE ratio of -241.3088235294118 and an FCF yield of 0.1525458390331464%.
Based on etftrends.comNatera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026
Natera Gains 118.1% in a Year: What's Driving the Rally?
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.